PB

Parthkumar Babulal Goyani

Active Director Managing Director DIN 07885789
DIN 07885789 First appointment Jul 2017 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Jul 2017
Shareholding value •••• Premium profile

About Parthkumar Babulal Goyani

Data last updated:

Parthkumar Babulal Goyani is a Managing Director at Speciality Medicines Limited (since 2021), Director at Spemed Techno Private Limited (since 2018) and Director at Uniza Speciality Private Limited (since 2024). The companies operate in Trading, Pharma and Paper. The 2 current companies with reported revenue have a combined latest revenue of ₹24.12 Cr; the largest is Speciality Medicines Limited at ₹23.26 Cr (FY 2023). Earlier, Parthkumar Babulal Goyani was a Director at Times Medicament Private Limited (2020–2024) and Director at Identixweb Limited (2017–2019).

DIN 07885789
Primary Designation Managing Director
Industry Trading
First Appointment 28 Jul 2017
Oldest Company Age 8 yrs
Largest company Speciality Medicines Limited · ₹23.26 Cr (FY 2023)
Combined revenue ₹24.12 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Speciality Medicines Limited U85300GJ2021PLC120022
Managing Director05 Feb 20212021₹23.26 Cr (FY 2023)Active
Spemed Techno Private Limited U52609GJ2018PTC100565
Director16 Jan 20182018₹86 Lakh (FY 2024)Active
Uniza Speciality Private Limited U21001GJ2024PTC157533
Director30 Dec 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Times Medicament Private Limited U85110GJ2020PTC113895
Director10 Jun 20202020Active
Identixweb Limited U72100GJ2017PLC098473
Director28 Jul 20172017₹9.21 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Uniza Speciality Private Limited
Spemed Techno Private Limited
Speciality Medicines Limited
Times Medicament Private Limited
Premium access

Shareholding and investment profile for Parthkumar Babulal Goyani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Parthkumar Babulal Goyani

Parthkumar Babulal Goyani currently holds 3 directorships: Speciality Medicines Limited (Managing Director, since 05 Feb 2021, revenue ₹23.26 Cr (FY 2023)); Spemed Techno Private Limited (Director, since 16 Jan 2018, revenue ₹86 Lakh (FY 2024)); Uniza Speciality Private Limited (Director, since 30 Dec 2024).

Parthkumar Babulal Goyani was first appointed on 28 Jul 2017 as Director at Identixweb Limited. The most recent appointment on record is 30 Dec 2024 at Uniza Speciality Private Limited.

The 2 current companies of Parthkumar Babulal Goyani that report revenue have a combined latest revenue of ₹24.12 Cr: Speciality Medicines Limited ₹23.26 Cr (FY 2023); Spemed Techno Private Limited ₹86 Lakh (FY 2024).

Parthkumar Babulal Goyani held 2 earlier board appointments: Times Medicament Private Limited (Director, 10 Jun 2020 to 18 Mar 2024); Identixweb Limited (Director, 28 Jul 2017 to 05 Nov 2019).

The current boards of Parthkumar Babulal Goyani's companies include Archana Madhav Bhayani (Speciality Medicines Limited), Bhaveshkumar Ashokbhai Savani (Speciality Medicines Limited), Chandresh Madhubhai Unagar (Speciality Medicines Limited), Kalpesh Bharatbhai Pipaliya (Speciality Medicines Limited), Sumeet Babulal Goyani (Speciality Medicines Limited), Milindkumar Saurinbhai Parikh (Uniza Speciality Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available